[Single center experience with bevacizumab in a cohort of patients treated for a relapsing glioblastoma].

CONCLUSION: This single center retrospective experience suggests that bevacizumab is active for recurrent glioblastoma, in a series of poorly selected patients. Median survival times were in the range of those reported in therapeutic trials. This study questions the validity of usual predictive factors in the era of bevacizumab. PMID: 26916405 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26916405?dopt=Abstract

Source: Presse Medicale - February 22, 2016 Category: Journals (General) Authors: Mbagui R, Ricard D, Vallard A, Magne N, Dulou R, Lahutte M, Calcina P, Taillia H, Yordanova Y, Delmas JM, Bauduceau O, Chargari C Tags: Presse Med Source Type: research